E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic myelomonocytic leukaemia (CMML) |
|
E.1.1.1 | Medical condition in easily understood language |
CMML is a form of leukaemia characterised by high numbers of white blood cells called monocytes in the blood and bone marrow. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10009018 |
E.1.2 | Term | Chronic myelomonocytic leukaemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. Is tefinostat (CHR-2845) safe and tolerable for patients with CMML?
2. Is tefinostat clinically effective in CMML? (primary efficacy endpoint will be overall clinical response rate according to the International Consortium MDS/MPN Response Criteria).
|
|
E.2.2 | Secondary objectives of the trial |
1. Is tefinostat clinically effective in CMML? (Secondary efficacy endpoint will include the incidences of complete remission, partial remission and 'haematological improvement', overall survival, progression-free survival, and time to transformation to acute myeloid leukaemia. )
2. Do clinical responses to tefinostat correlate with biological measures (including baseline hCE-1 expression level [Human carboxylesterase], differential effects on protein acetylation between monocytes and other haematological cell lineages and molecular mutational profile including targeted gene sequencing?) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients with newly-diagnosed or previously-treated CMML meeting WHO criteria with the following characteristics will be eligible for the study:
1. All CMML-2 patients are eligible 2. For patients classified as CMML-1, the following must be present:
• Symptomatic bone marrow failure / myeloproliferation defined as one or more of: red cell transfusion dependence with pre-transfusion Hb <90g/l, symptomatic anaemia (Hb <115g/l), thrombocytopenia (platelets <50 x 109/l), mptomatic bleeding due to platelet function defect or DIC/fibrinolysis, hite blood cell count >50 x 109/l
and/or
• CMML-specific Prognostic Score (CPSS) of intermediate-2 or high risk (16) (details of derivation of CPSS score given below)
and/or
• Systemic symptoms including weight loss with no alternative explanation (10% of baseline weight within previous 6 months) • Symptomatic splenomegaly • Symptomatic extrameduallary involvement, eg. skin infiltration, serous effusions
3. Subject is able and willing to sign the Informed Consent Form 4. Age greater than or equal to 18 years at the time of signing the Informed Consent Form 5. Willingness to undergo scheduled assessments as per the study protocol including bone marrow assessments 6. ECOG performance status of 0-2 at study entry 7. Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to starting study drug 8. Women of childbearing potential must use at least two effective contraceptive methods throughout the study and for three months following the date of the last dose of study drug 9. Men whose partner is a woman of childbearing potential must use at least two effective contraceptive methods
|
|
E.4 | Principal exclusion criteria |
1. CMML with eosinophillia and 5q33 abnormality 2. Previous chemotherapy for CMML except Hydroxycarbamide and 5-azacitidine 3. Creatinine concentration > 2x the institutional upper limit of normal range 4. Liver transaminases (AST / ALT) > 3x the institutional upper limit of normal range or serum bilirubin > 4x the institutional upper limit of normal range 5. Pregnant or lactating females 6. Use of experimental drug or therapy within 28 days of registration 7. Other malignancy within the last 3 years other than curatively-treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated non-metastatic prostate cancer with negative prostate-specific antigen, in situ breast carcinoma after complete surgical resection, or superficial transitional cell bladder carcinoma 8. Known seropositivity for HIV infection or infectious hepatitis (type B or C) 9. Uncontrolled inter-current illness including, but not limited to, ongoing infection, psychiatric illness or social situation that the treating physician judges would limit compliance with study requirements |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Safety and tolerability of tefinostat defined as the proportion of patients experiencing CTC grade 3-4 non-haematological toxicity or death thought to be at least possibly related to tefinostat.
2. Overall clinical response rate (according to International Consortium MDS/MPN Response Criteria) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Overall clinical response rate will be defined as the cumulative proportion of patients achieving clinical benefit (or better) according to International Consortium MDS/MPN Response Criteria(28) at day 29 of the sixth or last cycle of tefinostat (whichever is the earliest).
Patients will be followed up for 18 months to gather all data to effectively assess end points. |
|
E.5.2 | Secondary end point(s) |
- Incidence and duration of complete remission / partial remission / clinical benefit (according to International Consortium MDS/MPN Response Criteria)
- Overall clinical response rate (according to Wattel and modified IWG criteria) - Achievement of red blood cell and platelet transfusion independence - Overall survival - Progression-free survival - Incidence of transformation of CMML to AML (and time to AML transformation) - Duration of tefinostat therapy - Quality of life - Biological correlates including hCE-1 expression and changes in protein acetylation |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Patients will be followed up for 18 months to gather all data to effectively assess end points. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Patients will be followed up for a minimum of 18 months (to assess overall survival and progression free survival) following registration, or for 30 days after the last trial treatment if this exceeds 18 months.
The end of trial will be 6 months after the last data capture. This will allow sufficient time for the completion of protocol procedures, data collection and data input. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |